Coherus Oncology priced an underwritten public offering of 28,600,000 shares of common stock at $1.75 per share.
Gross proceeds expected to be approximately $50.1 million before underwriting discounts and expenses.
Underwriters granted a 30-day option to purchase up to an additional 4,290,000 shares.
Offering expected to close on or about February 17, 2026, subject to customary closing conditions.
Net proceeds to support commercialization of LOQTORZI® (toripalimab-tpzi), clinical development, working capital, and general corporate purposes.
Joint bookrunners:
TD Cowen, Guggenheim Securities, and Oppenheimer & Co.
Announcement dated February 12, 2026.